Academic Journal

Efficacy of bupropion and varenicline genetic markers in choosing pharmacological treatment for smoking cessation, and implications for combining drugs: A randomized controlled trial (GENTSMOKING)

التفاصيل البيبلوغرافية
العنوان: Efficacy of bupropion and varenicline genetic markers in choosing pharmacological treatment for smoking cessation, and implications for combining drugs: A randomized controlled trial (GENTSMOKING)
المؤلفون: Patricia V. Gaya, Juliana R. Santos, Paulo R. X. Tomaz, Tania M. O. Abe, Miguel Nassif Jr, Larissa G. Galas, Bianca B. Bellini, Iana R. Moraes, Paulo C. Lima Santos, Paulo C. R. P. Correa, Jaqueline R. Scholz
المصدر: Tobacco Induced Diseases, Vol 22, Iss April, Pp 1-12 (2024)
بيانات النشر: European Publishing, 2024.
سنة النشر: 2024
المجموعة: LCC:Diseases of the respiratory system
LCC:Neoplasms. Tumors. Oncology. Including cancer and carcinogens
مصطلحات موضوعية: precision medicine, varenicline, bupropion, smoking cessation, pharmacogenetics, Diseases of the respiratory system, RC705-779, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
الوصف: Introduction Smoking cessation is the best strategy for reducing tobacco-related morbimortality. The goal of this randomized controlled trial was to test whether using the genetically favorable markers to choose a smoking cessation drug treatment (precision medicine) was superior to using the most effective drug (varenicline) in terms of abstinence rates. Additionally, combination therapy was tested when monotherapy failed. Methods This partially blind, single-center study randomized (1:1) 361 participants into two major groups. In the genetic group (n=184), CYP2B6 rs2279343 (genotype AA) participants started treatment with bupropion, and CHRNA4 rs1044396 (genotype CT or TT) participants started treatment with varenicline; when genetic favorable to both, participants started treatment with bupropion, and when favorable to neither, on both drugs. In the control group (n=177), participants started treatment with varenicline, regardless of genetic markers. Drug treatment lasted 12 weeks. Efficacy endpoints were abstinence rates at Weeks 4, and Weeks 8–12, biochemically validated by carbon monoxide in exhaled air. Participants who did not achieve complete abstinence at Week 4, regardless of group, were given the choice to receive combination therapy. Results Abstinence rates were 42.9% (95% CI: 36–64) in the control group versus 30.4% (95% CI: 23–37) in the genetic group at Week 4 (p=0.01); and 74% (95% CI: 67–80) versus 52% (95% CI: 49–64) at Week 12 (p
نوع الوثيقة: article
وصف الملف: electronic resource
اللغة: English
تدمد: 1617-9625
Relation: https://www.tobaccoinduceddiseases.org/Efficacy-of-bupropion-and-varenicline-genetic-markers-in-choosing-pharmacological,186072,0,2.html; https://doaj.org/toc/1617-9625
DOI: 10.18332/tid/186072
URL الوصول: https://doaj.org/article/72f7581397d5419dbaa1483f7e78027c
رقم الانضمام: edsdoj.72f7581397d5419dbaa1483f7e78027c
قاعدة البيانات: Directory of Open Access Journals
الوصف
تدمد:16179625
DOI:10.18332/tid/186072